Project Grant R00EB035647
- The National Institute of Biomedical Imaging and Bioengineering (part of the Department of Health and Human Services National Institutes of Health) awarded $1.314 million to Massachusetts General Hospital on June 2, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop quantitative point-of-care MRI for breast cancer screening. The research addresses the limitations of current breast cancer screening modalities by...
- The National Institute of Biomedical Imaging and Bioengineering awarded Northeastern University $219,818 on April 27, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a fully integrated electro-optic sensor for real-time MRI-guided interventions. The award funds development of an interventional device sensor that addresses safety and imaging limitations in MRI-guided procedures. Current active devices for...
- This $1,336,000 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the CFDA 93.286 "Discovery and Applied Research for Technological Innovations to Improve Human Health" program supports the development of a rapid, motion-robust, and low-gadolinium MRI technology for pediatric brain tumors. The key objectives are to (1) develop cutting-edge technologies for rapid, motion-robust, and quantitative MRI scans to reduce sedation needs...
- The National Institute of Biomedical Imaging and Bioengineering awarded Vanderbilt University Medical Center $499,651 on June 4, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and validate a prospective head motion correction system for brain MRI using wireless NMR probes. The project addresses motion artifact in MRI, particularly in pediatric imaging, by creating a real-time motion tracking and correction...
- Federal Grant Award Summary Massachusetts General Hospital received a $165,000 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. The award supports research focused on modeling and safety assessment of magnetic spinal cord stimulation (MSCS), an...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Michigan $149,264 on March 26, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop magnetic resonance fingerprinting (MRF) technology for myocardial tissue characterization in patients with cardiac implantable electronic devices. The project addresses the clinical underutilization of cardiac MRI in CIED...
- The National Institute of Mental Health awarded Massachusetts General Hospital $453,750 under the Mental Health Research Grants program (CFDA 93.242) on September 1, 2026, to develop a closed-loop system for assessing target network engagement using concurrent transcranial magnetic stimulation and functional MRI. The recipient is developing a flexible radiofrequency coil array (the RF Cap) that enables functional MRI acquisition simultaneously with transcranial magnetic stimulation in a...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Leland Stanford Junior University $217,500 on April 10, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop portable resonance gradient coils for faster MRI with simplified calibration and real-time image reconstruction. The project addresses limitations in MRI encoding speed that constrain exam duration, scheduling availability, and...
- The National Institute of Biomedical Imaging and Bioengineering awarded Sloan-Kettering Institute for Cancer Research $636,110 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop motion-tolerant pediatric MRI technology that reduces anesthesia dependence in tumor imaging. The funded research develops deep learning reconstruction techniques combined with radial k-space acquisition to compensate for...
- The National Institute of Biomedical Imaging and Bioengineering awarded The General Hospital Corporation (Massachusetts General Hospital) $100,000 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop a quantum-inspired computational framework for advanced positron emission tomography (PET) imaging. The project addresses clinical gaps in PET's ability to detect small lesions, distinguish subtle treatment effects, and reduce radiation dose. The framework...
The National Institute of Biomedical Imaging and Bioengineering awarded The General Hospital Corporation (Massachusetts General Hospital) $249,000 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop engineering strategies that reduce the electromagnetic shielding burden of conventional superconducting MRI systems. The recipient will design, optimize, and experimentally validate passive and active radiofrequency radiation cancellation approaches for unshielded MRI operation. The work combines electromagnetic absorbers with advanced RF transmit strategies, including parallel transmit and radiation control arrays, to suppress MRI-induced radiofrequency radiation while preserving excitation fidelity. This effort builds on prior K99-phase feasibility work that established electromagnetic models of radiation from unshielded systems and demonstrated initial mitigation using both passive absorbers and active transmit-array approaches. The R00-phase goal is to develop scalable engineering strategies enabling MRI systems to meet electromagnetic compatibility limits without costly Faraday shielding, thereby reducing siting costs and improving access to high-performance imaging in rural and resource-limited settings. Performance occurs at the recipient's location in Charlestown, Massachusetts, with a period of performance from September 1, 2026 through May 31, 2029. This is a Project Grant assistance type.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $249.0k | 8/21/26 |